Personalized Medicine Coalition Announces Two New Board Members

Respected Leaders in the Diagnostics Industry Add to Depth and
Breadth of PMC Board
WASHINGTON--(Business Wire)--
The Personalized Medicine Coalition (PMC) today announced the
appointment of Pierre G. Cassigneul, president and chief executive
officer of XDx, Inc., and David P. King, chief executive officer,
president and director of Laboratory Corporation of America(R)
Holdings (LabCorp(R)) (NYSE: LH), to its Board of Directors. The PMC,
an educational and advocacy group dedicated to advancing the
understanding and adoption of personalized medicine, was launched in
2004 by more than 15 leading pharmaceutical, biotechnology,
diagnostics, and information technology companies, as well as major
academic centers and governmental agencies, and now includes over 140
members representing all the stakeholders with an interest in
personalized medicine.

"We have been very fortunate over the last five years to have a
Board of Directors that consists of highly respected individuals who
are actively reshaping the face of healthcare," said Edward Abrahams,
Executive Director of the PMC. "Pierre Cassigneul and David King are
no exception, and both will be tremendous assets to our Board. Their
combined expertise in the diagnostics industry and passion about our
mission will greatly assist the PMC's efforts to create a friendlier
landscape for personalized medicine."

Cassigneul, chief executive officer and president of XDx, Inc.,
has more than 20 years of international senior management experience
in the healthcare and medical device industries, including the launch
of several successful high-tech products. XDx, a molecular diagnostics
company, is one of the first companies to develop and commercialize
practical applications built on insights from the Human Genome
Project. Before joining XDx, Cassigneul served in top management
positions at Stone Bridge Management LLC, Becton Dickinson & Co.,
Bayer, Ortho Diagnostics Systems (J&J) and Abbot Laboratories.
Cassigneul holds a management degree from the Ecole Superieure de
Commerce de Reims in France.

"I am honored to join the Board of the PMC," said Cassigneul. "For
providers of products and services to be able to deliver on the
promise of personalized medicine, policymakers must intelligently and
comprehensively review the array of issues that affect the science and
clinical practice of personalized medicine. PMC is uniquely positioned
to address these issues and ensure a coherent, integrated approach to
the legal, financial, social and professional issues that will shape
the development and application of personalized medicine."

Also joining is David P. King, chief executive officer, president
and director of Laboratory Corporation of America Holdings (LabCorp).
A pioneer in genomic testing and the commercialization of new
diagnostic technologies, LabCorp is one of the world's largest
clinical laboratories. Prior to becoming chief executive officer in
2007, King served as LabCorp's executive vice president of strategic
planning and corporate development and chief operating officer since
2005. King's career at LabCorp followed a distinguished legal career
from 1992 to 2001 as a partner at Hogan & Hartson, L.L.P., where he
served as LabCorp's outside counsel. King holds an AB degree from
Princeton University and a JD degree from the University of
Pennsylvania Law School.

"I look forward to working with the rest of the Board to advance
PMC's efforts to influence critical policy decisions in the coming
years," King said. "PMC is the only organization that brings together
thought leaders from every part of the healthcare industry to explore
critical issues that will impact the future of medicine. LabCorp is
proud to assist PMC's efforts to promote the emergence of personalized
medicine as a critical part of the future of healthcare."

About the Personalized Medicine Coalition

The Personalized Medicine Coalition (PMC), representing a broad
spectrum of academic, industrial, patient, provider, and payer
communities, seeks to advance the understanding and adoption of
personalized medicine concepts and products for the benefit of
patients. For more information on the Personalized Medicine Coalition,
please visit www.PersonalizedMedicineCoalition.org.

About XDx, Inc.

Based in Brisbane, California, XDx is a molecular diagnostics
company focused on the discovery, development and commercialization of
noninvasive gene expression-based tests for the monitoring of
transplant rejection and autoimmune diseases. The company has
developed a proprietary new method for noninvasively monitoring immune
system activity by measuring gene expression in a patient's peripheral
blood. This work is the basis for AlloMap molecular expression
testing, which provides transplant physicians with a new tool to aid
in the identification of the probability of acute cellular rejection
for postcardiac transplant patient management. Some of the AlloMap
molecular expression technology developed and implemented by XDx in
heart transplant patient management may be applicable to other
diseases that involve transplant rejection and the immune system.
XDx's noninvasive technology offers the potential to decrease
healthcare costs and significantly improve the quality of life for
patients with a variety of life-threatening or life-altering
immune-mediated diseases. For more information on XDx, please visit
the company's website at www.xdx.com.

About LabCorp(R)

Laboratory Corporation of America(R) Holdings, a S&P 500 company,
is a pioneer in commercializing new diagnostic technologies and the
first in its industry to embrace genomic testing. With annual revenues
of $4.1 billion in 2007, over 26,000 employees nationwide, and more
than 220,000 clients, LabCorp offers clinical assays ranging from
routine blood analyses to HIV and genomic testing. LabCorp combines
its expertise in innovative clinical testing technology with its
Centers of Excellence: The Center for Molecular Biology and Pathology,
National Genetics Institute, Inc., ViroMed Laboratories, Inc., The
Center for Esoteric Testing, DIANON Systems, Inc., US LABS, and
Esoterix and its Colorado Coagulation, Endocrine Sciences, and
Cytometry Associates laboratories. LabCorp conducts clinical trial
testing through its Esoterix Clinical Trials Services division.
LabCorp clients include physicians, government agencies, managed care
organizations, hospitals, clinical labs, and pharmaceutical companies.
To learn more about our organization, visit our Web site at:
www.labcorp.com.

Personalized Medicine Coalition
Edward Abrahams, Executive Director
202-589-1770
or
Laboratory Corporation of America
Eric Lindblom, 336-436-6739
or
Pure Communications
Sheryl Seapy, 949-608-0841

Copyright Business Wire 2008